[96a5a0]: / output / allTrials / identified / NCT06638294_identified.json

Download this file

265 lines (265 with data), 11.3 kB

  1
  2
  3
  4
  5
  6
  7
  8
  9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
{
"info": {
"nct_id": "NCT06638294",
"official_title": "A Translational Observational Biorepository and Management Study in Patients With Breast Cancer Leptomeningeal Metastasis: The BioLept Study",
"inclusion_criteria": "* Male or female, aged 18 or older\n* History of breast cancer (any subtype)\n* Suspected breast cancer-related leptomeningeal metastasis (i.e., by clinical signs or symptoms (i.e., peri-oral dysesthesia, unexplained new neurological symptoms in the absence of brain metastasis), radiographic, or by cerebrospinal fluid analysis), whereby patient will be treated along an leptomeningeal disease paradigm.\n* Previous central nervous system metastasis (including leptomeningeal disease or brain metastasis) is eligible.\n* Eastern Cooperative Oncology Group (ECOG) score of ≤3 or Karnofsky performance status ≥60.\nHealthy volunteers allowed\nMust have minimum age of 18 Weeks",
"exclusion_criteria": "* Suspected central nervous system recurrence of hematologic malignancy, lymphoma or other solid tumor\n* Not eligible for treatment of leptomeningeal disease.",
"miscellaneous_criteria": ""
},
"inclusion_lines": [
{
"line": "* Male or female, aged 18 or older",
"criterions": [
{
"exact_snippets": "Male or female",
"criterion": "gender",
"requirements": [
{
"requirement_type": "presence",
"expected_value": [
"male",
"female"
]
}
]
},
{
"exact_snippets": "aged 18 or older",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum age",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "years"
}
}
]
}
]
},
{
"line": "* History of breast cancer (any subtype)",
"criterions": [
{
"exact_snippets": "History of breast cancer (any subtype)",
"criterion": "breast cancer",
"requirements": [
{
"requirement_type": "history",
"expected_value": true
},
{
"requirement_type": "subtype",
"expected_value": "any"
}
]
}
]
},
{
"line": "* Suspected breast cancer-related leptomeningeal metastasis (i.e., by clinical signs or symptoms (i.e., peri-oral dysesthesia, unexplained new neurological symptoms in the absence of brain metastasis), radiographic, or by cerebrospinal fluid analysis), whereby patient will be treated along an leptomeningeal disease paradigm.",
"criterions": [
{
"exact_snippets": "Suspected breast cancer-related leptomeningeal metastasis",
"criterion": "breast cancer-related leptomeningeal metastasis",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "clinical signs or symptoms (i.e., peri-oral dysesthesia, unexplained new neurological symptoms in the absence of brain metastasis)",
"criterion": "clinical signs or symptoms of leptomeningeal metastasis",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "radiographic",
"criterion": "radiographic evidence of leptomeningeal metastasis",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "cerebrospinal fluid analysis",
"criterion": "cerebrospinal fluid analysis for leptomeningeal metastasis",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* Previous central nervous system metastasis (including leptomeningeal disease or brain metastasis) is eligible.",
"criterions": [
{
"exact_snippets": "Previous central nervous system metastasis (including leptomeningeal disease or brain metastasis)",
"criterion": "central nervous system metastasis",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "leptomeningeal disease",
"criterion": "leptomeningeal disease",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "brain metastasis",
"criterion": "brain metastasis",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* Eastern Cooperative Oncology Group (ECOG) score of ≤3 or Karnofsky performance status ≥60.",
"criterions": [
{
"exact_snippets": "Eastern Cooperative Oncology Group (ECOG) score of ≤3",
"criterion": "ECOG score",
"requirements": [
{
"requirement_type": "score",
"expected_value": {
"operator": "<=",
"value": 3,
"unit": "N/A"
}
}
]
},
{
"exact_snippets": "Karnofsky performance status ≥60",
"criterion": "Karnofsky performance status",
"requirements": [
{
"requirement_type": "score",
"expected_value": {
"operator": ">=",
"value": 60,
"unit": "N/A"
}
}
]
}
]
},
{
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "healthy"
}
]
}
]
},
{
"line": "Must have minimum age of 18 Weeks",
"criterions": [
{
"exact_snippets": "minimum age of 18 Weeks",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "Weeks"
}
}
]
}
]
}
],
"exclusion_lines": [
{
"line": "* Suspected central nervous system recurrence of hematologic malignancy, lymphoma or other solid tumor",
"criterions": [
{
"exact_snippets": "Suspected central nervous system recurrence of hematologic malignancy",
"criterion": "central nervous system recurrence",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "Suspected central nervous system recurrence of ... lymphoma",
"criterion": "central nervous system recurrence",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "Suspected central nervous system recurrence of ... other solid tumor",
"criterion": "central nervous system recurrence",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* Not eligible for treatment of leptomeningeal disease.",
"criterions": [
{
"exact_snippets": "Not eligible for treatment of leptomeningeal disease.",
"criterion": "treatment of leptomeningeal disease",
"requirements": [
{
"requirement_type": "eligibility",
"expected_value": false
}
]
}
]
}
],
"miscellaneous_lines": [],
"failed_inclusion": [],
"failed_exclusion": [],
"failed_miscellaneous": []
}